Glonghui May 27 丨 Fosun Pharma (600196)(02196roshimmortalitycubeslot.HK) issued an announcement that the company's holding subsidiaries Jinzhou Aohong Pharmaceutical Co., Ltd. and Liaoning Children's Pharmaceutical Co., Ltd. recently received a report from the State Food and Drug Administration on diclorineroshimmortalitycubeslotTadine oral solution (hereinafter referred to as "the new drug") is used to relieve chronic idiopathic urticaria and allergic rhinitisroshimmortalitycubeslotDrug registration approval for systemic and local symptoms.
This new drug is a chemical independently developed by the group and is mainly used to relieve the systemic and local symptoms of chronic idiopathic urticaria and allergic rhinitis.
As of April 2024, the Group's cumulative R & D investment in this new drug at this stage is approximately RMB 8.17 million (unaudited).
As of the date of this announcement, in addition to this new drug, other desloratadine products that have been approved for marketing in China (excluding Hong Kong, Macao and Taiwan regions, the same below) mainly include Fubiding from Hainan Puli Pharmaceutical (300630) Co., Ltd., Baixinha from Wante Pharmaceutical (Hainan) Co., Ltd., desloratadine syrup from Chengdu Tongdaotang Pharmaceutical Co., Ltd., Sichuan, etc. According to the latest data from IQVIACHPA, sales of desloratadine products in China in 2023 will be approximately RMB3roshimmortalitycubeslot.15 billion yuan.
